Member Info for Bermudashorts

Looks like a late breaking abstract featuring research using Parsortix has been published and will be presented at AACR on Wednesday - link below. It appears to be completely independent research from Northwestern University, Chicago on culturing breast cancer CTC's captured by the Parsortix system. 'Using the Parsortix System, highly purified CTCs (ranging in number from 300 to 17,250 cells) were isolated from the blood samples for each of the 16 patients and placed into culture (day 0). During the first week, the CTCs could be expanded to 3.5 - 5.5 fold, and then to 9.5 - 22.5 fold during the second week, to maximum amount of 112,500 within 14 days' 'We identified and optimized a workflow for the recovery and culturing of CTCs from Stage III/IV BCa patients, demonstrating that cell-size dependent isolation using the Parsortix System allows for effective ex vivo culture. With further optimization, this strategy may be utilized for organoids development for drug testing and molecular analysis, representing an important tool for personalized precision therapy.' So capturing live circulating tumour cells from breast cancer patients and basically growing them in the lab - amazing and of course not possible with ctDNA liquid biopsies. http://www.abstractsonline.com/pp8/#!/4562/presentation/10780

More news on gene therapy for rare diseases today with the deal between GSK and Orchard Therapeutics. Amryt's deal with University College Dublin is looking becoming more and more interesting and looking forward to finding out more as they develop the EB gene therapy treatment. https://globenewswire.com/news-release/2018/04/12/1468962/0/en/GSK-signs-strategic-agreement-to-transfer-rare-disease-gene-therapy-portfolio-to-Orchard-Therapeutics.html

Worth noting the deal announced this morning by Novartis who are paying $8.7b for Avexis. They are a Swiss biotech. specialising in gene therapy for rare diseases. Their lead candidate is in clinical trials for a condition spinal muscular atrophy - a rare disease affecting young children and with an estimated market of just 23,500. Of course Amryt now also has a gene therapy platform in development for rare diseases, including EB following their deal with University College Dublin. https://www.bloomberg.com/news/articles/2018-04-09/novartis-to-pay-8-7-billion-for-gene-therapy-company-avexis

Great news that the first patient has now been recruited to Angle's pivotal breast cancer trial. Will be interesting to hear further updates. One line from the RNS jumped out:- "A positive result in this clinical study would demonstrate the potential for Abbott to offer a Parsortix-based product for HER-2 analysis from a routine blood test." For any new to this stock, Abbott, one of the World's largest diagnostics/medical devices companies, have a collaboration agreement with Angle and have contributed to this trial. HER-2 testing is routinely performed on all breast cancer patients. It can also be tested on other cancer types - ovarian, bladder and lung. Currently HER-2 testing is performed using tissue biopsies taken from the tumour. The problem is that HER-2 status can change over time but you can't monitor a patient's status by operating regularly to take tissue biopsies. You can imagine the potential market for a liquid biopsy test that could monitor HER-2 status via a simple regular blood test and more importantly the potential impact on selecting the best treatment for that patient. Would be fantastic if Angle could become the first ever company to receive FDA approval for for a product harvesting intact circulating tumour cells (CTCs) from patient blood - not long to wait until we find out. https://clinicaltrials.gov/ct2/show/NCT03427450?term=parsortix&rank=1

Nice mention here for Amryt and their newly acquired EB gene therapy https://bv.world/tech/science-technology/2018/03/sweet-gene-victory-around-the-corner-therapeutic-advances-come-rolling-in/

Courtesy of Clausentum on ADVFN, the Clinical Trials Register has now been updated to show that Angle's pivotal breast cancer trial is now recruiting. Excellent news. https://clinicaltrials.gov/ct2/show/NCT03427450?term=parsortix&cond=Breast+Cancer+AND+%22Neoplastic+Cells%2C+Circulating%22&rank=1

Thoth, Completely agree regarding markets being big enough for more than one new treatment. Just to clarify though, ALL lupus trials are carried out with both treatment and placebo arms continuing to receive SOC treatment - this isn't anything specific to Lupuzor. You'll find that unless the FDA soften their stance any lupus therapy developed by SAR would also have the same trial protocol.

Thanks for the heads up.

Wow - you couldn't make it up. Who would have thought things could get any worse here. "analysis of data from this first patient indicates that their systemic RXC004 exposure was significantly higher than that predicted from preclinical studies" How is that possible? Very much hope that the patient is OK, the toxicity was quickly dealt with and has left no lasting effects. https://investegate.co.uk/redx-pharma-plc--redx-/rns/rxc004-clinical-trial-update/201803290700073245J/

Seems like Summit's new antibiotic for gonorrhoea is urgently required. http://www.bbc.co.uk/news/health-43571120 https://investegate.co.uk/summit-therapeutics-plc--summ-/gnw/summit-s-infectious-diseases-technology-platfor---/20180313110023H5740/

Yep, nicely handled. Only a small discount, no warrants, quick and clean.

Malachi, That's correct Angle have a pivotal breast cancer trial headed up by MD Anderson and other centres include USC and Wilmot Cancer Centre in the US. The abstract did include unpublished results. Previously we had only received top line results for the ovarian trial but Dr Richard Moore presented the full detailed results at the SGO Meeting over the weekend.

The conference referred to in The Sunday Times article is the SGO Annual Meeting on Women's Cancer which is taking place this weekend in New Orleans. It's a highly prestigious scientific conference and Prof. Richard Moore was presenting the results of the Ovarian study. The link to the abstract is below https://sgo.confex.com/sgo/2018/meetingapp.cgi/Paper/10215

Yes, link below courtesy of Waterloo. Great stuff. https://www.thetimes.co.uk/article/shares-in-angle-to-jump-on-ovarian-cancer-test-news-0fmbpf25k

We assume so but have no way of knowing for sure.

A few months delay in a phase III trial is a small price to pay given the reason for the delay. The ability to refine trial protocol based on lessons learned from Amicus could be the difference between success and failure. Very generous of Amicus to share their data. Generally, a cracking update from AMYT today. More detail on in-licenced gene therapy programme from University College Dublin is below. http://www.ucd.ie/charles/research/researchprogrammes/geneticdiseasescancer/epidermolysisbullosa/

monkster, Yes, obviously very early stage and there's a long way to go but could be an important development for Summit. Some sound bites from the RNS:- It is estimated by the WHO that there are approximately 106 million new cases of gonorrhoea globally per year. There is now only one treatment recommended by the CDC, a combination of two antibiotics. increasing resistance and a lack of innovation means we are now nearing an era of untreatable disease In early testing, the new series of antibiotic compounds has been shown to have high potency against strains of gonorrhoea with no development of resistance to date The Company believes the identified series of antibiotic compounds has the potential to produce a new front-line therapy for gonorrhoea.

"Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces the discovery of a series of antibiotic compounds that kill gonorrhoea bacteria via new mechanisms of action." https://investegate.co.uk/summit-therapeutics-plc--summ-/gnw/summit-s-infectious-diseases-technology-platfor---/20180313110023H5740/

Yes, another distribution agreement for Lojuxta and management team strengthened with the addition of Jordi Casals to push European development. "This is Amryt�s fifth new distribution agreement for Lojuxta in approximately three months" https://www.irishtimes.com/business/health-pharma/amryt-pharma-signs-distribution-agreement-in-middle-east-1.3416584#.Wp5Ju3gnafU.twitter

Link to Andrew Newland's Shares Magazine is below. https://www.youtube.com/watch?v=NL3-S4OUywQ